| scholarly article | Q13442814 |
| P50 | author | Javier Escalada | Q60395309 |
| Jordi Salas-Salvadó | Q35028955 | ||
| Pedro Valdivielso | Q46055616 | ||
| P2093 | author name string | Juan Pedro-Botet | |
| Xavier Pintó | |||
| Vivencio Barrios | |||
| Juan F Ascaso | |||
| Pablo Pérez-Martínez | |||
| Alejandro De la Sierra | |||
| Jesús Millán | |||
| Jose M Mostaza | |||
| P2860 | cites work | Aspirin for primary prevention of cardiovascular events in people with diabetes, etc. | Q22241289 |
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Fibrates for secondary prevention of cardiovascular disease and stroke | Q24186376 | ||
| Lipoprotein(a) as a cardiovascular risk factor: current status | Q24623225 | ||
| Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials | Q24645391 | ||
| Inflammation, obesity, and thrombosis | Q27008937 | ||
| A Randomized Trial of Intensive versus Standard Blood-Pressure Control | Q27231406 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 | ||
| Effect of valsartan on the incidence of diabetes and cardiovascular events | Q28275975 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
| Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Q29619465 | ||
| Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study | Q51939995 | ||
| International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material | Q53384061 | ||
| Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis | Q53842804 | ||
| 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). | Q55057254 | ||
| Prevention of Diabetes With Mediterranean Diets | Q56627460 | ||
| Diagnóstico de síndrome metabólico. Adecuación de los criterios diagnósticos en nuestro medio. Recomendaciones del foro HDL. Resumen ejecutivo | Q58210832 | ||
| Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk | Q61409365 | ||
| Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases | Q79507169 | ||
| Metabolic syndrome, haemostasis and thrombosis | Q81389911 | ||
| Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II | Q83213188 | ||
| The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study | Q84099952 | ||
| Hemostatic factors and the metabolic syndrome | Q86605379 | ||
| [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients] | Q86889702 | ||
| [Delphi consensus on management of dyslipidaemia in patients with impaired glucose metabolism: Diana study] | Q87416386 | ||
| [Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9] | Q87457958 | ||
| 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the E | Q88263238 | ||
| [Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study] | Q88322170 | ||
| 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clini | Q50043295 | ||
| Prevalence of metabolic syndrome according to different definitions in a hypertensive population | Q51034935 | ||
| Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects. | Q51070889 | ||
| Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance | Q51161029 | ||
| Venous thromboembolism--a manifestation of the metabolic syndrome | Q51476313 | ||
| Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. | Q51571152 | ||
| Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study | Q51756663 | ||
| 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q29620108 | ||
| Mendelian randomization in cardiometabolic disease: challenges in evaluating causality | Q30234302 | ||
| Fibrates for primary prevention of cardiovascular disease events. | Q30241199 | ||
| Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness | Q33607601 | ||
| Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia | Q33646780 | ||
| The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. | Q33701262 | ||
| The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg | Q33750634 | ||
| Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation | Q34021093 | ||
| 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres | Q34046881 | ||
| Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject. | Q34104492 | ||
| Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association | Q34153132 | ||
| Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management | Q34181381 | ||
| Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? | Q34361973 | ||
| An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report | Q34404312 | ||
| Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial | Q34527453 | ||
| 2. Classification and Diagnosis of Diabetes | Q34547458 | ||
| Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation | Q34567335 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Metabolic syndrome and incident diabetes: current state of the evidence | Q34790658 | ||
| Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement | Q34964056 | ||
| Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat | Q35006662 | ||
| Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials | Q35024182 | ||
| Major lipids, apolipoproteins, and risk of vascular disease | Q35771393 | ||
| Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial | Q35777145 | ||
| Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk | Q36027260 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Resist diabetes: A randomized clinical trial for resistance training maintenance in adults with prediabetes. | Q36288380 | ||
| Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. | Q36313988 | ||
| Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis | Q36341675 | ||
| Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? | Q36478676 | ||
| Protective Effects of the Mediterranean Diet on Type 2 Diabetes and Metabolic Syndrome. | Q36728465 | ||
| Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovascular disease | Q37032603 | ||
| Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes | Q37308578 | ||
| Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients | Q37437052 | ||
| Role of adipose tissue in haemostasis, coagulation and fibrinolysis. | Q37491351 | ||
| Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events | Q37797672 | ||
| Revisiting the links between glycaemia, diabetes and cardiovascular disease | Q38077060 | ||
| New medications for treatment of obesity: metabolic and cardiovascular effects | Q38347675 | ||
| New insights into the pathophysiology of dyslipidemia in type 2 diabetes | Q38364277 | ||
| AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. | Q38431722 | ||
| Main characteristics of metabolically obese normal weight and metabolically healthy obese phenotypes | Q38507577 | ||
| Metabolic syndrome update | Q38665336 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology | Q38740078 | ||
| 5. Prevention or Delay of Type 2 Diabetes | Q39040076 | ||
| Pitavastatin: A Review in Hypercholesterolemia | Q39107221 | ||
| Connecting the Metabolic and Immune Responses to Cancer | Q39232711 | ||
| Metabolic syndrome is associated with muscle symptoms among statin users. | Q39437849 | ||
| Lipoprotein (a), the Metabolic Syndrome and Vascular Risk in Angiographied Coronary Patients. | Q39704605 | ||
| Primary Prevention of Cardiovascular Disease in Diabetes Mellitus | Q40087045 | ||
| Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. | Q40196417 | ||
| [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects]. | Q40456575 | ||
| A modified Mediterranean diet score is associated with a lower risk of incident metabolic syndrome over 25 years among young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study | Q41705138 | ||
| Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. | Q43649801 | ||
| Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment | Q44350203 | ||
| Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population | Q44420225 | ||
| Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk | Q44439740 | ||
| Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease | Q44513189 | ||
| The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). | Q44722477 | ||
| Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). | Q44954018 | ||
| Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension | Q44990922 | ||
| National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report | Q45012753 | ||
| Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. | Q45959391 | ||
| Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. | Q46209361 | ||
| Platelet reactivity and response to aspirin in subjects with the metabolic syndrome | Q46210875 | ||
| Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using R | Q46429835 | ||
| Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus | Q46795016 | ||
| Metabolic syndrome and asymptomatic peripheral artery disease in subjects over 60 years of age. | Q46865033 | ||
| Postprandial coagulation activation in overweight individuals after weight loss: acute and long-term effects of a high-monounsaturated fat diet and a low-fat diet. | Q47192690 | ||
| 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial | Q47233232 | ||
| Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. | Q47364504 | ||
| A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management | Q47377383 | ||
| Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | Q47765250 | ||
| Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease | Q47895914 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | metabolic syndrome | Q657193 |
| P304 | page(s) | 683-697 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | Q5270108 |
| P1476 | title | COSMIC project: consensus on the objectives of the metabolic syndrome in clinic | |
| P478 | volume | 11 |
| Q89820044 | The Effect of Autophagy on Chronic Intermittent Hypobaric Hypoxia Ameliorating Liver Damage in Metabolic Syndrome Rats | cites work | P2860 |
Search more.